4D Molecular Therapeutics Inc. - notizie pubblicate 182 - letture 4.806
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
4d-175 comprises the proprietary low-dose intravitreal r100 aav vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor h (scf ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4DMT to Present Initial Interim 24 week Landmark Analysis from the 4D 150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
24-week landmark safety and clinical activity data for 45 patients enrolled in the population extension cohort expected to be presented (n=30 at 3e10 vg/eye) clinical data will be ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Presents Injection Free Subgroup Analyses from 4D 150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
Injection-free subgroup results demonstrated that a single intravitreal dose of 4d-150 without any supplemental anti-vegf injections resulted in stable mean visual acuity that was ...
4D MOLECULAR THERAPEUTICS INC.
Material Agreement Form 8 K
Item 1.01 entry into a material definitive agreement. on june 7, 2024, 4d molecular therapeutics, inc. (the "company") entered into a sales agreement (the "sales agr ...
4D MOLECULAR THERAPEUTICS INC.
Supplemental Prospectus - Form 424B5
424b5 table of contents filed pursuant to rule 424(b)(5) registration no. 333-276872 prospectus supplement (to prospectus dated february 5, 2024) up to $250,000,000 common stock we ...
4D MOLECULAR THERAPEUTICS INC.
4D-710 AEROW Phase 1/2 Interim Clinical Data – June 2024
Aerosolized 4d-710 for the treatment of cystic fibrosis (cf) lung disease interim phase 1/2 safety & efficacy data and program update june 6, 2024 © 2024 4d molecular©2024 4d ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D 710 for Modulator Ineligible/ Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
Clinically meaningful improvements in ppfev1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppfev1 50-80%) and >6 months f ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
• 24-week injection-free subgroup analyses from the randomized phase 2 dose expansion stage of prism trial evaluating 4d-150 in wet amd patients with severe disease activity and ...
4D MOLECULAR THERAPEUTICS INC.
4DMT to Participate in Upcoming Investor Conferences
Emeryville, calif., june 03, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on u ...
4D MOLECULAR THERAPEUTICS INC.
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
Interim clinical data will be presented by jennifer l. taylor-cousar, m.d., principal investigator of the aerow clinical trial at the 47th european cystic fibrosis conference on th ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti